1. Bong, Ivyna Pau Ni, Ng, Ching Ching, Othman, Norodiyah, Esa, Ezalia. 2022. Gene expression profiling and in vitro functional studies reveal RAD54L as a potential therapeutic target in multiple myeloma. In Genes & genomics, 44, 957-966. doi:10.1007/s13258-022-01272-7. https://pubmed.ncbi.nlm.nih.gov/35689754/
2. Avsar, Timucin, Mohiyuddin, Rashid, Calis, Seyma, Yapicier, Ozlem, Kilic, Turker. . Association of MTHFR, MTRR and RAD54L Gene Variations with Meningioma and Correlation with Tumor's Histopathological Characteristics on Turkish Cohort. In Turkish neurosurgery, 31, 587-593. doi:10.5137/1019-5149.JTN.33347-20.2. https://pubmed.ncbi.nlm.nih.gov/34169999/
3. Wang, Yinzhao, Zhou, Tailai, Chen, Hengxing, Dao, Pinghong, Chen, Minfeng. 2022. Rad54L promotes bladder cancer progression by regulating cell cycle and cell senescence. In Medical oncology (Northwood, London, England), 39, 185. doi:10.1007/s12032-022-01751-7. https://pubmed.ncbi.nlm.nih.gov/36071250/
4. Li, Hongda, Zhuang, Haiwen, Gu, Tengfei, Xu, Sanrong, Zhou, Qing. 2023. RAD54L promotes progression of hepatocellular carcinoma via the homologous recombination repair pathway. In Functional & integrative genomics, 23, 128. doi:10.1007/s10142-023-01060-w. https://pubmed.ncbi.nlm.nih.gov/37071224/
5. Felicio, Paula S, Grasel, Rebeca S, Campacci, Natalia, Carraro, Dirce M, Palmero, Edenir I. 2020. Whole-exome sequencing of non-BRCA1/BRCA2 mutation carrier cases at high-risk for hereditary breast/ovarian cancer. In Human mutation, 42, 290-299. doi:10.1002/humu.24158. https://pubmed.ncbi.nlm.nih.gov/33326660/
6. Liu, Changjiang, Ren, Wei, Zhang, Zhixin, Guan, Juanjuan. 2022. DNA repair/recombination protein 54L promotes the progression of lung adenocarcinoma by activating mTORC1 pathway. In Human cell, 36, 421-433. doi:10.1007/s13577-022-00832-z. https://pubmed.ncbi.nlm.nih.gov/36454390/
7. Li, Likun, Karanika, Styliani, Yang, Guang, Yin, Jianhua, Thompson, Timothy C. 2017. Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. In Science signaling, 10, . doi:10.1126/scisignal.aam7479. https://pubmed.ncbi.nlm.nih.gov/28536297/
8. Liu, Xiaoyi, Wei, Qinglv, Yang, Chenyue, Liu, Tao, Yi, Ping. 2024. RNA m5C modification upregulates E2F1 expression in a manner dependent on YBX1 phase separation and promotes tumor progression in ovarian cancer. In Experimental & molecular medicine, 56, 600-615. doi:10.1038/s12276-024-01184-4. https://pubmed.ncbi.nlm.nih.gov/38424195/
9. Olmos, D, Lorente, D, Alameda, D, Herrera-Imbroda, B, Castro, E. 2024. Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes. In Annals of oncology : official journal of the European Society for Medical Oncology, 35, 458-472. doi:10.1016/j.annonc.2024.01.011. https://pubmed.ncbi.nlm.nih.gov/38417742/
10. Wang, Zhenwei, Zheng, Zongtai, Wang, Bangqi, Zhong, Zhihui, Qiu, Xiaofu. 2024. Characterization of a G2M checkpoint-related gene model and subtypes associated with immunotherapy response for clear cell renal cell carcinoma. In Heliyon, 10, e29289. doi:10.1016/j.heliyon.2024.e29289. https://pubmed.ncbi.nlm.nih.gov/38617927/